O	0	8	Managing
O	9	12	the
O	13	17	risk
O	18	20	of
O	21	29	invasive
O	30	36	breast
O	37	43	cancer
O	44	46	in
O	47	52	women
O	53	55	at
O	56	60	risk
O	61	64	for
O	65	71	breast
O	72	78	cancer
O	79	82	and
O	83	95	osteoporosis
O	95	96	:
O	97	100	the
O	101	105	role
O	106	108	of
B-intervention	109	119	raloxifene
O	119	120	.

O	121	131	Raloxifene
O	132	145	hydrochloride
O	146	148	is
O	149	150	a
O	151	160	selective
O	161	169	estrogen
O	170	178	receptor
O	179	188	modulator
O	189	190	(
O	190	194	SERM
O	194	195	)
O	196	200	that
O	201	204	has
O	205	219	antiestrogenic
O	220	227	effects
O	228	230	on
O	231	237	breast
O	238	241	and
O	242	253	endometrial
O	254	260	tissue
O	261	264	and
O	265	275	estrogenic
O	276	283	effects
O	284	286	on
O	287	291	bone
O	291	292	,
O	293	298	lipid
O	299	309	metabolism
O	309	310	,
O	311	314	and
O	315	320	blood
O	321	329	clotting
O	329	330	.

O	331	341	Raloxifene
O	342	355	significantly
O	356	364	improves
O	365	370	serum
O	371	377	lipids
O	378	381	and
O	382	387	serum
O	388	395	markers
O	396	398	of
O	399	413	cardiovascular
O	414	421	disease
O	422	426	risk
O	426	427	,
O	428	431	but
O	432	434	it
O	435	438	has
O	439	441	no
O	442	453	significant
O	454	460	effect
O	461	463	on
O	464	467	the
O	468	472	risk
O	473	475	of
O	476	483	primary
O	484	492	coronary
O	493	499	events
O	499	500	.

O	501	502	A
O	503	507	meta
O	507	508	-
O	508	516	analysis
O	517	519	of
O	520	530	randomized
O	530	531	,
O	532	538	double
O	538	539	-
O	539	544	blind
O	544	545	,
O	546	553	placebo
O	553	554	-
O	554	564	controlled
O	565	571	trials
O	572	574	of
O	575	585	raloxifene
O	586	589	for
O	590	602	osteoporosis
O	603	609	showed
O	610	613	the
O	614	618	odds
O	619	621	of
B-outcome	622	630	fracture
I-outcome	631	635	risk
O	636	640	were
O	641	642	0
O	642	643	.
O	643	645	60
O	646	647	(
O	647	649	95
O	649	650	%
O	651	661	confidence
O	662	670	interval
O	671	672	[
O	672	674	CI
O	674	675	]
O	676	677	=
O	678	679	0
O	679	680	.
O	680	682	49
O	682	683	-
O	683	684	0
O	684	685	.
O	685	687	74
O	687	688	)
O	689	692	for
O	693	703	raloxifene
O	704	706	60
O	707	709	mg
O	709	710	/
O	710	713	day
O	714	722	compared
O	723	727	with
B-control	728	735	placebo
O	735	736	.

O	737	743	During
O	744	745	8
O	746	751	years
O	752	754	of
O	755	761	follow
O	761	762	-
O	762	764	up
O	765	767	in
O	768	770	an
O	771	783	osteoporosis
O	784	789	trial
O	789	790	,
O	791	794	the
O	795	805	raloxifene
O	806	811	group
O	812	815	had
O	816	817	a
B-iv-bin-percent	818	820	76
I-iv-bin-percent	820	821	%
O	822	831	reduction
O	832	834	in
O	835	838	the
B-outcome	839	848	incidence
I-outcome	849	851	of
I-outcome	852	860	invasive
I-outcome	861	863	ER
I-outcome	863	864	-
I-outcome	864	872	positive
I-outcome	873	879	breast
I-outcome	880	886	cancer
O	887	895	compared
O	896	900	with
O	901	904	the
O	905	912	placebo
O	913	918	group
O	918	919	.

O	920	922	In
O	923	926	the
O	927	931	STAR
O	932	937	trial
O	937	938	,
O	939	942	the
B-outcome	943	952	incidence
I-outcome	953	955	of
I-outcome	956	964	invasive
I-outcome	965	971	breast
I-outcome	972	978	cancer
O	979	982	was
B-iv-bin-abs	983	984	4
I-iv-bin-abs	984	985	.
I-iv-bin-abs	985	987	30
O	988	991	per
B-intervention-participants	992	996	1000
O	997	1002	women
O	1002	1003	-
O	1003	1008	years
O	1009	1013	with
O	1014	1024	raloxifene
O	1025	1028	and
B-cv-bin-abs	1029	1030	4
I-cv-bin-abs	1030	1031	.
I-cv-bin-abs	1031	1033	41
O	1034	1037	per
B-control-participants	1038	1042	1000
O	1043	1047	with
O	1048	1057	tamoxifen
O	1057	1058	;
O	1059	1061	RR
O	1062	1063	=
O	1064	1065	1
O	1065	1066	.
O	1066	1068	02
O	1068	1069	;
O	1070	1072	95
O	1072	1073	%
O	1074	1076	CI
O	1076	1077	,
O	1078	1079	0
O	1079	1080	.
O	1080	1082	82
O	1082	1083	-
O	1083	1084	1
O	1084	1085	.
O	1085	1087	28
O	1087	1088	.

O	1089	1092	The
O	1093	1099	effect
O	1100	1102	of
O	1103	1113	raloxifene
O	1114	1116	on
O	1117	1125	invasive
O	1126	1132	breast
O	1133	1139	cancer
O	1140	1143	was
O	1143	1144	,
O	1145	1154	therefore
O	1154	1155	,
O	1156	1166	equivalent
O	1167	1169	to
O	1170	1174	that
O	1175	1177	of
O	1178	1187	tamoxifen
O	1188	1192	with
O	1193	1197	more
O	1198	1207	favorable
O	1208	1213	rates
O	1214	1216	of
O	1217	1224	adverse
O	1225	1232	effects
O	1233	1242	including
B-outcome	1243	1250	uterine
I-outcome	1251	1261	malignancy
O	1262	1265	and
B-outcome	1266	1274	clotting
I-outcome	1275	1281	events
O	1281	1282	.

O	1283	1291	Millions
O	1292	1294	of
O	1295	1309	postmenopausal
O	1310	1315	women
O	1316	1321	could
O	1322	1328	derive
O	1329	1332	net
O	1333	1340	benefit
O	1341	1345	from
O	1346	1356	raloxifene
O	1357	1364	through
O	1365	1372	reduced
O	1373	1378	rates
O	1379	1381	of
O	1382	1390	fracture
O	1391	1394	and
O	1395	1403	invasive
O	1404	1410	breast
O	1411	1417	cancer
O	1417	1418	.
